东南亚和巴基斯坦概述：新兴的临床试验扩大中心

Southeast Asia andPakistan Overview: The Table of contents IQVIA Southeast Asia and Pakistan overviewIndonesia IQVIA Southeast Asia and Pakistan overview Southeast Asia and Pakistan represent competitive regions for clinical development, combining large, diverse,treatment-naïve populations with improving healthcare infrastructure. These markets enable efficient patientrecruitment and create vast opportunities to accelerate trial growth and innovation across multiple therapeutic areas. Site networks The presence of prime and partner networks in each location enables differentiated clinical trial execution, enhancingpatient recruitment and trial outcomes. Quality IQVIA R&DS site quality and performance in Southeast Asia is on par with mature markets in the key SUCCESS FACTORS FOR •Effective issue escalation•Proactive risk management•Oversight of audit inspections•Cross functional quality plan Clinical trial landscape During 2020-2024, approximately 49% of all trials were local, whereby approximately 45% were phase I and II. Oncology and infectious disease were the top therapeutic areas Others include Hepatology, Psychiatry, Women's Health/Sexual health, Acute care, Allergy/Immunology, Orthopedics, Transplantation, Medical genetics andother trials are related to safety and efficacy, bioavailability, pharmacokinetic and comparison studies etc. IQVIA footprint In the last 5 years, IQVIA R&DS was involved in ~16% of the global clinical trials in Southeast Asia across all Others include Rheumatology, Respiratory, Gastrointestinal, Ophthalmology,Women’s health/Sexual health, Psychiatry, Allergy/Immunolog y, Acute care,Hepatology, Nephrology and other trials are related to safety and efficac y, bio Indonesia Indonesia offers one of Southeast Asia’s largest patient pools.Established in 2006, IQVIA has secured full-service CRO license,ensuring streamlined regulatory processes and reliable trial Large population oftreatmentnaïve patients Quick turnaround timefor budget negotiation Indonesia clinical trial start-up (drugs, vaccine, biologics) Hospitals across Indonesia Indonesia clinical regulatory reform Reshaping of clinical Formation of Clinical Research •Clinical trial management atkey hospitals •Online application for EC, regulatoryapproval, permits (MTA) — enableeasy progress monitoring •One stop solution for clinical trialconduct in Indonesia diseases, andRespiratory diseases Malaysia Malaysia’s ethnically diverse population and advanced healthcareinfrastructure make it possible to generate multi-ethnic clinical COUNTRY OVERVIEW Regulatoryaccredited sites Ethnogenetic diversityTo enhance trial cohort variety,improving data generalizability Large patient accessPublic system does not routinelycover high-cost innovativetherapies. Clinical trials as a Regulatory efficiencyMalaysia’s regulatory bodiesensure predictable timelinesand transparent processes >600 Leading CRO in Malaysia,honored with the 8th CRO ofthe Year Award in 2025 with >20 Rated top 30 countryin IQVIA country Government supportthrough initiatives and community Malaysia clinical trial start-up Sites accredited for First-In-Human (FIF) studies Ampang hospital •Dedicated clinical trial unit establishedsince 2009•IQVIA partner site Malaysia’s hybrid decentralized solution Decentralized solution leveraging Malaysia’s health clinic network and Access Brings trials closer to patients. Malaysia’s dense healthcare network, Simplified experience Patients attend trial visits at nearby clinics with remote PI oversight via Retention Reduces patient burden, improves compliance, ensuring better trial continuity New clinical trial initiations by year Top 5 indications Philippines As the second most populous country in Southeast Asia, patientinterest in clinical trial participation remains high due to limited COUNTRY OVERVIEW Strong patient interest Over100 sites and >400investigatorsin different and high retention due tolimited standard-of-carereimbursement, with high Largest CROin the Philippineswith vast experience inOncology, Cardiovascular, Lower trial costscompared to western andother APAC countries With vast experience in usingdigital solutionsacross National practice guidelinesaligned with international Hosted4 PFDA, 1 CFDI, 1 EMAand5 USFDA inspectionswithout any critical findings Government and privatetertiary hospitalswith own English-speaking staff andmedical recordsin English Philippines clinical trial start-up process Clinical trial landscape CONTACT USSchedar Umandapschedar.umandap2@iqvia.comiqvia.com Vietnam Vietnam provides access to a large treatment-naïve population andrapidly expanding research sites. IQVIA leads the way as Vietnam’sfirst global CRO with a wholly-owned foreign enterprise licensed COUNTRY OVERVIEW Over 102M population,with a large treatment-naïvecohort across multiple TA Robust investigator and siteecosystem,with >60 MOHGCP-accredited hospitals and Strong fou